Chinese drug regulator gives green light to mass distribution of Sinopharm Jab after showing 79% effectiveness – RT World News


    Pékin a approuvé un vaccin contre le coronavirus développé par le China National Pharmaceutical Group (Sinopharm), pour un usage public.  Il survient un jour après que l'inoculation a montré une efficacité de près de 80%.

</p><div><p>Le vaccin a reçu le feu vert de la National Medical Products Administration, l'agence chinoise de réglementation des médicaments et des dispositifs médicaux, a déclaré jeudi un responsable de la surveillance lors d'une conférence de presse.

The decision paves the way for a widespread rollout of the vaccine across the country, making it the first vaccination to receive the green light for a mass vaccination campaign in the original pandemic hotspot.

Approval is conditional as testing is still ongoing. A day before the announcement, the developer of the state-owned vaccine revealed that preliminary analysis of the phase three trial showed it to be safe to use and 79.34% effective against Covid-19.

Also on
Chinese Sinopharm vaccine is 79% effective, developer says, citing results from phase 3 trial

Although inoculation was the brainchild of Sinopharm’s subsidiary, China National Biotec Group, China was not the first country to allow the vaccine to be used by the general public – the UAE has sanctioned the vaccine for massive use earlier this month. However, UAE’s own trials, conducted earlier in December, showed an effectiveness rate of around 86% higher.

Sinopharm’s vaccine is one of many Chinese inoculations in the advanced phase of testing. Since the summer, Beijing has distributed around 1.5 million doses of two different Sinopharm products across the country, as well as a product developed by Sinovac, through emergency use legislation.

Do you think your friends would be interested? Share this story!


Please enter your comment!
Please enter your name here